Systemic mast cell disease without associated hematologic disorder: A combined retrospective and prospective study

被引:26
作者
Pardanani, A
Baek, JY
Li, CY
Butterfield, JH
Tefferi, A
机构
[1] Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Div Hematopathol, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Div Allerg Dis & Internal Med, Rochester, MN 55905 USA
关键词
D O I
10.4065/77.11.1169
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective:. To study clinicopathologic correlations and identify prognostically-important variables in patients with systemic mast cell disease (SMCD) who have no associated hematologic disorders. Patients and Methods: We, identified 40 adult patients with SMCD with. out associated hematologic disorders. Clinical, laboratory, and bone,marrow (BM) histologic findings at the, time of referral were evaluated (November 1980-February 2001) for possible correlations with a history of aggressive systemic mastocytosis (retrospectively analyzed) as well-as survival (prospectively analyzed). Results: The median follow-up time from diagnosis was 108 months and from BM examination was 24 months. A history of aggressive systemic mastocytosis correlated significantly with increased BM mast cell (MC) content, and unfavorable MC infiltration pattern, BM eosinophilia, and elevated serum alkaline phosphatase (SAP) level, but not with BM angiogenesis, reticulin fibrosis, or levels of MC mediators of these factors, increased BM MC content and elevated SAP level were also associated with shortened survival from. time of referral. Conclusions: This study suggests that the BM MC. burden, BM eosinophilia, and SAP level are prognostically important in SMCD without associated hematologic disorders. In contrast. BM angiogenesis, reticulin fibrosis, and levels of MC mediators showed no prognostic relevance.
引用
收藏
页码:1169 / 1175
页数:7
相关论文
共 39 条
[1]   Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis [J].
Akin, C ;
Kirshenbaum, AS ;
Semere, T ;
Worobec, AS ;
Scott, LM ;
Metcalfe, DD .
EXPERIMENTAL HEMATOLOGY, 2000, 28 (02) :140-147
[2]   SYSTEMIC MASTOCYTOSIS [J].
AUSTEN, KF .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (09) :639-640
[3]   THE CHRONIC MYELOID LEUKEMIAS - GUIDELINES FOR DISTINGUISHING CHRONIC GRANULOCYTIC, ATYPICAL CHRONIC MYELOID, AND CHRONIC MYELOMONOCYTIC LEUKEMIA - PROPOSALS BY THE FRENCH-AMERICAN-BRITISH-COOPERATIVE-LEUKEMIA-GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, H ;
SULTAN, C ;
COX, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (04) :746-754
[4]  
BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x
[5]   PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&
[6]   PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) :620-625
[7]   Human mast cells stimulate vascular tribe formation - Tryptase is a novel, potent angiogenic factor [J].
Blair, RJ ;
Meng, H ;
Marchese, MJ ;
Ren, SL ;
Schwartz, LB ;
Tonnesen, MG ;
Gruber, BL .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (11) :2691-2700
[8]   c-Kit and c-kit mutations in mastocytosis and other hematological diseases [J].
Boissan, M ;
Feger, F ;
Guillosson, JJ ;
Arock, M .
JOURNAL OF LEUKOCYTE BIOLOGY, 2000, 67 (02) :135-148
[9]   Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis [J].
Escribano, L ;
Díaz-Agustín, B ;
Bellas, C ;
Navalón, R ;
Nuñez, R ;
Sperr, WR ;
Schernthaner, GH ;
Valent, P ;
Orfao, A .
LEUKEMIA RESEARCH, 2001, 25 (07) :563-570
[10]   World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997 [J].
Harris, NL ;
Jaffe, ES ;
Diebold, J ;
Flandrin, G ;
Muller-Hermelink, HK ;
Vardiman, J ;
Lister, TA ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) :3835-3849